SCHEDULE 13G/A: BlackRock Discloses 5.0% Passive Stake in ADC Therapeutics SA

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 5.0% passive beneficial ownership stake in ADC Therapeutics SA as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 1 to Schedule 13G concerning its beneficial ownership in ADC Therapeutics SA.
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 4,913,153 shares of ADC Therapeutics SA's Common Stock.
• This ownership represents 5.0% of the total class of securities outstanding.
• BlackRock, Inc. holds sole voting power over 4,860,912 shares and sole dispositive power over 4,913,153 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of ADC Therapeutics SA.
• BlackRock, Inc. is classified as a Parent Holding Company or Control Person (HC, HC) for this filing.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing itself is a routine disclosure of a passive stake by a major institutional investor, which can be seen as a positive signal of confidence in the issuer, ADC Therapeutics SA. However, it contains no specific operational or financial news to drive strong sentiment.

Positives

• The disclosure of a 5.0% stake by BlackRock, Inc., a major institutional investor, can be viewed as a vote of confidence in ADC Therapeutics SA.
• The passive nature of the investment indicates that BlackRock does not intend to influence or change the control of the issuer, suggesting stability from a governance perspective.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding ADC Therapeutics SA's future performance or BlackRock's future investment intentions beyond the passive nature of the current holding.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing indicates a significant institutional investment in ADC Therapeutics SA, a company likely operating in the biotechnology or pharmaceutical sector. Such passive stakes are common for large asset managers like BlackRock, reflecting portfolio diversification or strategic allocation within the healthcare industry, rather than a direct commentary on specific industry trends or competitive dynamics.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports a beneficial ownership stake and does not provide financial or operational results for comparison. Therefore, a direct comparison to industry-specific performance benchmarks or competitor results is not applicable based on the content provided.

Stakeholder Impact

• Shareholders: The disclosure of a 5.0% passive stake by BlackRock, Inc. may be viewed positively by existing shareholders as it indicates significant institutional interest and potential stability in the stock.
• Investment Professionals: Provides transparency regarding a major institutional investor's position in ADC Therapeutics SA, aiding in market analysis and investment decisions.

Next Steps

• The document does not specify any future actions or milestones for ADC Therapeutics SA or BlackRock, Inc. beyond the ongoing passive holding.

Key Dates

Keywords

ADC Therapeutics SA, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing